Hepatocellular carcinoma (HCC) remains the fourth leading cause of cancer‐related death
worldwide. However, the clinical diagnosis and treatment modalities are still relatively …

Transarterial chemoembolization (TACE) is a recommended treatment for patients suffering
from intermediate and advanced hepatocellular carcinoma (HCC). As compared to the …

The cancer mortality rate of hepatocellular carcinoma (HCC) is the second highest in the
world and the therapeutic options are limited. The incidence of this deadly cancer is rising at …

Because diagnostic tools for discriminating between hepatocellular carcinoma (HCC) and
advanced cirrhosis are poor, HCC is often detected in a stage where transarterial …

Metabolic-associated fatty liver disease (MAFLD) is a chronic liver disease characterized by
fatty infiltration of the liver. In recent years, the MAFLD incidence rate has risen and emerged …

Simple Summary Transarterial chemoembolization (TACE) is a guideline-approved,
minimally invasive therapy for unresectable hepatocellular carcinoma (HCC). This study …

Drug-eluting beads transarterial chemoembolization (DEB-TACE) is an alternative to
conventional lipiodol-based TACE (cTACE) to treat hepatocellular carcinoma (HCC). With …

Hepatocellular carcinoma (HCC) is one of the most common malignant cancer in the world,
which greatly threatens human health. However, the routine treatment strategies for HCC …

Commercially available drug-eluting embolization beads (100–500 μm) reduced the
occurrence of adverse events related to an anticancer drug, but were unascertained to …

Background: This study aimed to compare the efficacy and safety of 70–150 μm doxorubicin
drug-eluting bead (DEB) transarterial chemoembolization (TACE) with those of 100–300 μm …